 |
 |

First-Choice Treatment in Mild to Moderate Obstructive Sleep ApneaSingle-Stage, Multilevel, Temperature-Controlled Radiofrequency Tissue Volume Reduction or Nasal Continuous Positive Airway Pressure
Kursat Ceylan, MD ;
Hatice Emir, MD;
Zeynep Kizilkaya, MD;
Eren Tastan, MD;
Ahmet Yavanoglu, MD;
Hakk Uzunkulao lu, MD;
Erdal Samim, MD;
Sevim Arslan Felek, MD
Arch Otolaryngol Head Neck Surg. 2009;135(9):915-919.
Objective To compare the efficacy of single-stage, multilevel, temperature-controlled radiofrequency tissue volume reduction (TCRFTVR) for the soft palate and base of the tongue with that of nasal continuous positive airway pressure (CPAP) in primary treatment of mild to moderate obstructive sleep apnea.
Design A prospective nonrandomized clinical study.
Setting Tertiary care referral center.
Patients Data from 47 patients with mild to moderate obstructive sleep apnea treated between January 1, 2003, and October 31, 2006, were reviewed.
Interventions Twenty-six patients underwent TCRFTVR and 21 underwent nasal CPAP as a primary treatment modality.
Main Outcome Measures Baseline and 12-month posttreatment measurements using the Epworth Sleepiness Scale and polysomnography were compared.
Results The baseline characteristics of the groups were not significantly different. Both methods showed meaningful results for the Epworth Sleepiness Scale and polysomnography variables 12 months after treatment compared with baseline measurements. The results were not significantly different in the posttreatment intergroup comparisons. Treatment success rates were 52.4% for nasal CPAP and 53.8% for TCRFTVR (P = .92).
Conclusion Similar comparison results with nasal CPAP in objective and subjective variables make single-stage, multilevel TCRFTVR a good alternative in primary treatment of mild to moderate obstructive sleep apnea.
Author Affiliations: Ear, Nose, and Throat Department, Ministry of Health, Ankara Training and Research Hospital, Ankara, Turkey.
Deceased.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|